FMW Media Work announces that its "New to The Street Leadership," Powered by Sector SPDR ETFs, will air on Bloomberg TV as sponsored programming on Saturday, February 24, 2024, at 6:30 PM ET, and the "New to The Street" business show will air on the FOX Business Network, Monday, February 26, 2024, at 10:30 PM PT.

The "New to The Street Leadership" show airs on Bloomberg TV as sponsored programming on Saturday, February 24, 2024, at 6:30 PM ET.

"New to The Street Leadership's" TV Co-Host Matt Doherty, Executive Coach, Media Personality, and Author, and TV Business Co-Host Jane King talks with two inspirational business leaders:

1). Tucker York, the Global Head of Goldman Sachs Wealth Management of The Goldman Sachs Group, Inc. ($GS).

2). Tim Pernetti, President of IMG Academy.

New to The Street Leadership's TV Co-hosts Matt Doherty and Jane King, from the Nasdaq MarketSite Studio, talk with Tucker York about his leadership role as the Global Head of Goldman Sachs Wealth Management division of The Goldman Sachs Group, Inc. ($GS) ("Goldman Sachs"). Since its inception in 1869, Goldman Sachs, a world-renowned investment banking firm, has prided itself on integrity, transparency, and investment performance, always looking to improve client relationships, employee atmosphere, and shareholder value. Tucker began his career with Goldman Sachs shortly after graduating from business school. In October 1987, Tucker was still a junior with Goldman when the October "Black Market" crash occurred. Since that day, that experience changed him forever in how he views clients' needs. With many years of dedicated expertise assisting Goldman's clients, Tucker became a managing director and partner at the firm in 1996 and 2000. Tucker informs viewers that Goldman always looks at risk management models, sharing those plans with its customers, employees, and shareholders. Good leaders want to find immediate solutions with the lowest possible losses that can sometimes come from unexpected events. Tucker's leadership skills have developed over the decades since 1987, and now, as the Global Head of Wealth Management, Tucker always looks for ways to improve client services, better interaction with employees, and strengthen shareholders' results and relations. Through comprehensive risk management plans, Goldman Sachs successfully navigated and maintained clients' confidence through some of the worst market events, 911, Housing Crises, and COVID-19. Risk management employees constantly look at "the what if" scenarios to put in place platforms to ensure the needs of their clients when adverse market events occur. Employee retention is an integral part of the overall success at Goldman Sachs. Happy employees engaged in ongoing operations are successfully servicing Goldman's extensive client base. Goldman Sachs has a minimal employee turnover rate, with many employees holding positions for decades. As a leader, he understands that change does occur, and knowing how to handle changes and communicate effectively is vital to building trust and long-lasting relationships. With different market gyrations and business and personal relationship encounters, stress can become a problem for the best of leaders. Tucker says influential leaders manage stress by looking at the direct cause and managing the outcome positively. The risk-reward ratio, long-term vs. short-term, and effectively acknowledging that ratio reduces client, employee, and shareholder stress; a good leader will always provide risk-avert solutions to the best of their ability, planning to diminish anxieties. The on-screen QR code is available during the show to download more info or visit The Goldman Sachs Group, Inc. - https://www.goldmansachs.com/ and Goldman Sachs Wealth Management - https://privatewealth.goldmansachs.com/us/en/home.

Tim Pernetti, the President of IMG Academy, from the Nasdaq MarketSite Studios, talks with New to The Street Leadership's TV Co-host Jane King about his leadership role at the prep school. As a leading sports education brand, IMG provides access and opportunities for student-athletes on-campus and online. The academy's model focuses on holistic and intentional personal development through a suite of products. A 600-acre campus in Bradenton, Florida, offers over 1500 students a practical education beyond just classroom instruction. The academy prides itself on a value proposition based on 4-core components: on-campus student life, academics, athletics, and athletic/personal development. Tim explains that IMG Academy is more than just sports training; it offers students practical life skills. Confidence building, endurance training, physical fitness, leadership skills, and mental/mindset tools are part of the educational experience. IMG is a proper college-prep academy offering 6-12 graders a full curriculum of studies to prepare them for college. J.J. McCarthy, the University of Michigan quarterback who recently won the National Football Championship, is an IMG Academy alum. He was a student during the COVID-19 shutdown and utilized IMG's numerous programs to help him prepare for college. As a successful quarterback, JJ learned meditation techniques offered to him while attending IMG. Today's students deal with social media, other online exposures, and social complexities, which can greatly affect demeanor and performance. IMG provides fantastic resources to handle daily social and academic issues. Athletics, personal development, and academics are equally balanced, giving students a highly structured environment with the quest to ensure college and lifetime success. Before becoming President of IMG, Tim worked as an executive for the academy through his relationship with Endeavor Group Holdings, Inc. In 2020, during COVID, his passion became more evident, and he took on a direct role as president. The academy is always looking to improve the student experience; they engage employees, students, and parents to provide comprehensive suggestions that can significantly benefit all the educational platforms on campus and online. He immediately saw a need for the academy to improve upon female programs. Girls' sports programs are an essential aspect of the IMG Academy curriculum, with new program offerings to inspire female athletes. Some of the most influential female athletes sit on IMG Academy's "Women in Sports Committee," providing leadership roles and advice to improve girls' sports educational experiences. Offering girls more student loan packages has increased female enrollments and helps maintain retention rates. The efforts proved successful with new sports curricula like the women's volleyball program. IMG Academy hosts numerous sports camps and college recruitment programs and has provided MLS (Major League Soccer), NFL, WNBA, and other sports teams' facilities and training programs. New facilities, sports programs, food services, and student life programs became realities based on those inputs shared with the academy's leaders. The positive ongoings have increased student enrollment and overall student body retention. IMG Academy's online presence, IMG Academy+, helps student-athletes globally with various programs. Endeavor Group Holdings, Inc. recently sold the IMG Academy to Hong Kong-based BPEA Equity (BPEA EQT), a private equity firm. BPEA EQT, in partnership with existing portfolio company Nord Anglia Education, can open IMG Academy's sports educational programs to a larger global market. With Tim's strong vision, leadership skills, and commitment to ensuring a unique sports educational experience, IGM Academy attracts some of the best student-athletes, helping them excel in their life's journey. The on-screen QR code is available during the show; download or visit IMG Academy - https://www.imgacademy.com/.

New to The Street's nationally broadcasted TV show airs on the Fox Business Network on Monday, February 26, 2024, at 10:30 PM PT.

New to The Street features the following six (6) Corporate interviews:

1). Biopharmaceutical - Tonix Pharmaceuticals, Inc.'s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, Chairman and CEO.

2). "Game Changers Segment" interview with PetVivo Holdings, Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) interview with John Lai, CEO/President.

3). Sustainable Solutions - VRM BioLogik® Group's (VRM) interview with Ken Bellamy, Founder and President.

4). Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

5). Coffee - NuZee, Inc.'s (NUZE) ($NUZE) interview with Masateru Higashida, Founder, Chairman, and CEO.

6). "Sekur Privacy & Sekur Security – Weekly Hack” segment with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF).

From the Nasdaq MarketSite Studio, Dr. Seth Lederman, MD, Chairman and CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) ("Tonix"), talks with New to The Street's TV Host Jane King about the Company's successful completion of Phase 3 studies on its fibromyalgia drug. Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia. The drug is a non-opioid, non-addictive painkiller. Since 2009, there have been no new fibromyalgia drugs available in the marketplace. Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in treatment success. Competitor drugs cause sleeplessness and low energy. Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish patient fatigue. The side effects are minimal, with around 3% of patients experiencing headaches and some drowsiness. Administered as a sublingual tablet, Tonmya™ has caused tongue numbness in a few patients. Patients take the drug at bedtime, which can block brain signals that are often associated with pain, and the drug has shown improved sexual functionality. Dr. Ledermen expects the Company to submit its full report to the FDA for market approval sometime during the first half of 2024, with a full approval expectation sometime in 2025. The on-screen QR code is available during the shows; download or visit Tonix Pharmaceuticals, Inc. - https://www.tonixpharma.com/.

New to The Street airs its "Game Changers Segment" with TV Host and Multi-media Journalist Ana Berry, who talks with John Lai, CEO/President of PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) ("PetVivo"). With creative therapeutic medical innovations for pets, PETV is a "Game Changer." Owners of dogs, cats, and horses are seeing remarkable results when using the Company's SPRYNG™ with OsteoCushion Technology ("SPRYNG™"), an intra-articular injectable veterinary medical device consisting of cellular matrix microparticles. Veterinarians are increasingly using the product as an alternative to surgery, helping pet owners manage pets with osteoarthritis and other joint-related ailments. John goes over three corporate milestones. First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease. The next milestone was the Company's ability to attract Covetrus North America, LLC, another largest veterinarian medical distributor; now, the three largest medical distributors carry SPRYNG™. In January 2024, the third milestone veterinarian doctors who were keynote speakers at the Veterinary Meeting & Expo (VMX) conference in Orlando, Florida, endorsing their successful use of the Company's SPRYNG™ product in small animal cases. Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses. The Company expects sales increases for product uses for small pets, dogs, and cats, as these recent studies, presentations, and distributors are educating pet owners and vets about SPRYNG™ positive treatment outcomes. The Company has five more pending studies, with expected results reported before the conclusion of 2024. PETV's SPRYNG™ with OsteoCushion Technology is a "Game Changer" medical device that successfully treats pets and gives owners options beyond surgeries. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. - https://petvivo.com/ & Spryng with OsteoCushion Technology - https://www.sprynghealth.com/.

New to The Street airs TV Host Jane King's interview with VRM BioLogik® Group's (VRM) Ken Bellamy, Founder and President. As a leading technology company utilizing microbial formulations, VRM is creating solutions for significant organic waste mitigation and recycling issues facing the planet. Ken explains that using organic catalysts and waste materials, the Company creates technologies that improve soils, increasing agricultural productivity and water conservation. VRM offers solutions to small growers and large governmental organizations to recycle organic waste into usable nutrient-rich products. Ken talks about VRM's participation in the COP 28 event in Dubai, where they showcased innovative solutions and case studies. VRM had the privilege of delivering a speech on behalf of the Government of Indonesia at the event, emphasizing the government's six years of experience and initiatives using VRM's innovative, environmentally sound technologies, products, and services. Currently, VRM is working with nine other countries seeking environmentally sound solutions to improve waste management conversion into usable products significantly. Global private and public entities are increasingly looking to improve crop yields and increase available agricultural acreage to eliminate food insecurities. VRM continues to find innovative technologies that can assist and repair the planet's ecosystem. The on-screen QR code is available during the show; download or visit VRM BioLogik® Group - https://www.vrm.science/.

New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had approximately 94% success with no reinfections. In treated patients, the microbiome bacteria found in the digestive tract shows the bacteria maintaining and restoring itself within those patients after a 10-day treatment. At a recent microbiome conference presentation in Texas, the Company compared logarithmic results from a competitor drug (vancomycin) to its Ibezapolstat drug, showing the differences in the effects on gut microbiome bacteria. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high and greatly diminished gut microbiome bacteria. ACXP's Ibezapolstat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for the newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. Throughout 2024, Investors and others should expect more exciting news about Ibezapolstat and other positive corporate ongoings. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.

New to The Street's TV Host Jane King is at the Nasdaq MarketSite Studio with Masateru Higashida, Founder, Chairman, and CEO of NuZee, Inc. (NUZE) ($NUZE) ("NuZee Coffee"). The Company leads in the co-packing for single-serve coffee formats, helping partners and other companies enter and expand into the single-serve coffee market. NuZee offers small coffee roasters to more prominent global brands, an end-to-end sustainable solution with flexibility and capacity to grow their market segments. Consumers want high-quality coffee, an on-the-go product that NuZee produces and sells globally, "Pour Over" and "Brew Bag" (Tea Bag Style) single-serve coffee. Popularity for the product began in Japan and is now gaining acceptance with US consumers. Masateru explains the Company's single-serve Pour-Over coffee co-branding partnership with Jimmy Butler's BIGFACE Brand. The Company has other co-branding relationships like the one with Stone Brewing, a prominent US craft beer company. Stone Brewing and NuZee see lots of synergies that can expand both companies' brands. Other opportunities exist globally as the Company evaluates direct marketing and co-branding strategies. Management is lowering costs from the reduced expenditures in fees paid to legal professionals, consultants, and non-performing advertisement firms. Throughout 2024, the Company believes revenues should increase on existing product lines from its sales/marketing campaigns while seeking more co-branding relationships in the US and globally. NuZee is working on new product innovations and will continue to grow its single-serve coffee product, which can be easily portable for travel, offices, and other events. The on-screen QR code is available during the show; download or visit NuZee, Inc. - https://mynuzee.com/.

Internationally acclaimed internet privacy expert Alain Ghiai, CEO, Sekur Private Data Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) and New to The Street TV Host / Multi-media Journalist Ana Berry present the "Sekur Privacy & Sekur Security – The Weekly Hack" segment. Ana and Alain discuss the topic of news media host Tucker Carlson and his recent interview with Russian President Vladimir Putin. Tucker Carlson has speculated that in 2021, the US NSA unmasked his internet identity and leaked emails to the media about his communications about interviewing the Russian president. If it did happen, as Carlson claims, unsecured email platforms are known to be vulnerable. Individuals and businesses with compromised emails account for 91% of the source of cybersecurity problems. Many individuals, companies, and governmental entities contract Big Tech platforms for email accounts and other technology services. When entering into agreements with Big Tech, the "Term of Use" language often confuses consumers, not realizing they allow technology service providers, in some cases, authorizations to track, store, and sell data. Recently, Google settled a lawsuit with end-users claiming web traffic spying activities while using the "incognito" browser mode. Alan suggests using a secure virtual private network that isn't on a Big Tech platform. Sekur's SekurVPN services allow end-users to appear always as operating in Switzerland, masking a subscriber's internet footprint. SekurVPN protects subscribers' digital identity and internet traffic as an encrypted platform. The Company and its fully controlled servers are in Switzerland, a country with the most stringent privacy laws. IP addresses are personal private property, and any compromised use of data is strictly prohibited. The Company's SekurVPN, SekurMail, and SekurMessenger services have enhanced encrypted security features that can significantly minimize end-users from a possible cyberattack. Alan offers PROMO CODE: PRIVACY; subscribers can get an additional 15% off monthly and yearly subscriptions for five years on any of the Company's subscriptions. Sekur Private Data, Ltd. never data mines, never sells data and never asks for a phone number. Viewers, please tune in next time for the newest cybersecurity topic on the "Sekur Privacy & Sekur Security– Weekly Hack" segment. The on-screen QR code is available during the shows to download more info or visit Sekur Private Data, Ltd. – https://sekurprivatedata.com/, http:/sekur.com/ and https://sekur.com/en/vpn. Privacy has arrived!

About Goldman Sachs Wealth Management:

Goldman Sachs Wealth Management advisors offer unparalleled resources, access, and guidance to help clients maximize their impact and wealth. A management advisor is deeply attuned to clients' goals and values and curates all Goldman Sachs has to offer. Invest using a time-tested approach for managing risk and building customized portfolios with long-term strategies for expected future success - https://privatewealth.goldmansachs.com/us/en/home.

About The Goldman Sachs Group, Inc. ($GS):

The Goldman Sachs Group, Inc. ($GS) is a leading global financial institution that delivers a broad range of financial services to a large and diversified client base, including corporations, financial institutions, governments, and individuals. The firm, founded in 1869, is headquartered in New York and maintains offices in all major financial centers worldwide - https://www.goldmansachs.com/.

About Tucker York, The Global Head of Goldman Sachs Wealth Management:

Tucker York is the Global Head of Goldman Sachs Wealth Management. He is a member of the Management Committee. Mr. York also serves on the Goldman Sachs Trust Company board and the Asset & Wealth Management Private Wealth Management Capital Committee. Before assuming his current role, Mr. York was Global Co-Head of the Consumer and Wealth Management Division. Before that, he served in various leadership roles across the global wealth management franchise, including Head of the US business and Co-Head of the EMEA business. Mr. York worked in Frankfurt, Zurich, London, and New York. He began his career covering clients in New York and continues in that capacity today as part of his overall responsibilities. Mr. York joined Goldman Sachs in 1986 in New York as a Private Wealth Advisor. He was named Managing Director in 1996 and Partner in 2000. Mr. York serves as Vice Chair of the Network for Teaching Entrepreneurship Board of Directors, Treasurer of the Board of Trustees at The Marymount School, and a trustee at Christ Church in New York City. He is also a member of the Chancellor's Philanthropic Council at the University of North Carolina at Chapel Hill (UNC) - https://www.goldmansachs.com/about-us/people-and-leadership/leadership/management-committee/tucker-york.html.

About IMG Academy:

IMG Academy is the world's leading sports education brand, providing access and opportunity for student-athletes with an innovative suite of on-campus and online programming. IMG Academy supports the entire student-athlete developmental journey from exploration to specialization to graduation through its boarding school and camps on its cutting-edge campus in Bradenton, Florida; IMG Academy+ online coaching with a focus on personal development through the lens of sport and performance; and NCSA College Recruiting, providing tools, coaching, and access to a network of 40,000 college coaches. IMG Academy is the only education brand directly responsible for filling one-quarter of all college roster spots annually. IMG Academy helped place many thousands of kids into college - https://www.imgacademy.com/.

About Tim Pernetti:

Tim Pernetti is the President of IMG Academy and is responsible for leading the campus and all businesses in IMG Academy's physical location in Bradenton, Florida. Tim joined IMG Academy in 2020 as Chief Operating Officer and was later promoted to President in Aug. 2022. In his role, he led a successful navigation of the COVID-19 pandemic, keeping IMG Academy open and fully operational during a critical time of uncertainty. Under Pernetti's leadership, IMG Academy is on an upward trajectory of growth, including the addition of a 15th sport (Girls Volleyball), sweeping changes to student-athlete and staff experience, and $100M of campus capital expansion, including the development of a state-of-the-art student campus center, construction of a fourth dormitory and the addition of new fields and training facilities. Before joining IMG Academy, Pernetti was an executive at Endeavor Group Holdings, Inc. ("Endeavor") from 2015 to 2020. Serving as Executive Vice President from 2019-20, he oversaw Endeavor and IMG sports, events, and entertainment properties within the IMG Events & Media team in North America and globally. Pernetti served as Chief Business Officer of the Major League Soccer (MLS) expansion club New York City FC (NYCFC) from 2013-2015, co-owned by Manchester City Football Club and the New York Yankees. He is a former football student-athlete at Rutgers University from 1989-93. Pernetti returned to his alma mater in 2009 as the youngest Director of Intercollegiate Athletics in college sports. From 1995 to 2009, Pernetti held numerous executive positions in the media. After stints as Director of Programming at ABC Sports, overseeing all college sports, PGA Tour, and other programming relationships, and Director of Programming & Production for ABC-TV, he was one of the first employees for startup CSTV (College Sports Television) in 2003. Pernetti is very active in community affairs - https://www.imgacademy.com/about-img-academy/media-brand#execs.

About Coach Matt Doherty and Doherty Coaching:

Matt Doherty is a nationally recognized motivational speaker, best-selling author, media personality, and executive coach. In 2022, he was named the Vistage Rookie of the Year and won the Chair Excellence Award. He guides corporations, C-suite managers, sales executives, and business and sports coaches to develop leadership skills and team dynamics. Since starting on the 1982 National Championship team with Michael Jordan at UNC, his journey has included being the Head Coach at Notre Dame and UNC. He was named the 2001 AP National Coach of the Year after leading the Tar Heels to the ACC Regular Season Championship and a #1 ranking. Matt was also the head coach at FAU and SMU and worked for ESPN, the Indiana Pacers, and the Atlantic 10 Conference. In 2003, he embarked on a mission to "Learn & Grow" by beginning a leadership journey at the UVA Darden School of Business and The Wharton School. Coach Doherty is committed to sharing universal teachings and actionable ideas that will work for anyone - https://www.dohertycoaching.com/.

About Sector SPDR ETFs:

Sector SPDR ETFs are unique ETFs that divide the S&P 500 into eleven sector index funds. Investors can customize their investments by picking and weighing each sector to meet specific investment goals. Sector SPDR ETFs have the diversification of a mutual fund, the focus of a sector fund, and the tradability of a stock. Investors can buy or sell Sector SPDR ETF shares on the NYSE Arca during trading hours. The eleven Sector SPDR ETFs represent the S&P 500. However, each Sector SPDR ETF can be purchased individually, providing undiluted exposure to a particular sector or industry group - https://www.sectorspdr.com/.

About "New to The Street Leadership" with Matt Doherty and Jane King Powered by Sector SPDR ETFs:

New to The Street Leadership with Matt Doherty and Jane King Powered by Sector SPDR ETFs is a monthly television show featuring individuals who lead their organization to successful outcomes and future endeavors. Guests will share their success stories and motivations, allowing viewers to understand and learn leadership skills. The show is co-hosted with Coach Matt Doherty and recognized business TV host Jane King. The show airs monthly, on the last Saturday of each month, on Bloomberg TV as a sponsored program - https://www.newtothestreet.com/.

About Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP):

Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) ("Tonix") is a biopharmaceutical company focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to reduce the severity of acute stress reaction and the frequency of acute stress disorder and post-traumatic stress disorder. This trial is being sponsored by the University of North Carolina and received funding support from the US Department of Defense. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and top-line results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA and received funding from the National Institute on Drug Abuse (NIDA). A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix's rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (PWS). The FDA has granted TNX-2900 Orphan Drug designation, and an investigational new drug (IND) application has been cleared to support a Phase 2 study in PWS patients. Tonix's immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the US National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Project NextGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.(*Tonix's product development candidates are investigational new drugs or biologics and have not been approved for any indication; Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.) - https://www.tonixpharma.com/.

About PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV):

PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale - https://petvivo.com/.

About Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP):

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) is a clinical-stage biopharmaceutical Company focused on developing new antibiotics for difficult-to-treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP). The Company's Ibezapolstat is a novel, orally administered antibiotic developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria species, appears to contribute to maintaining a healthy gut microbiome. The Company completed Phase 2 clinical trials of Ibezapolstat. To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.

About VRM Biologik:

VRM Biologik is a renowned biotech intellectual property development leader committed to revolutionizing various industries through innovative solutions. With a strong background in research and development, VRM Biologik aims to create sustainable and transformative products that address pressing global challenges. Their sustainable technologies are designed to address environmental challenges and promote a more sustainable future – https://vrmbiologik.com.

About NuZee, Inc. (NUZE) ($NUZE) "NuZee Coffee":

NuZee, Inc. (NUZE) ($NUZE) is a leading co-packing company for single-serve coffee formats. It partners with companies to help them expand within the single-serve and private-label coffee categories. By providing end-to-end innovative and sustainable solutions with the flexibility and capacity for both small roasters and large global brands, NuZee is revolutionizing how single-serve coffee is enjoyed in the US. Through the brand's unique process, NuZee fulfills every aspect of co-packing needs, from sourcing, roasting, and blending to packing and packaging - https://mynuzee.com/.

About Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF):

Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management. The Company distributes a suite of secure cloud-based storage, disaster recovery, document management, encrypted emails, and secure communication tools. It sells its products through its websites, www.sekur.com, approved distributors, and telecommunication companies worldwide. Sekur Private Data, Ltd. serves consumers, businesses, and governments worldwide - https:/sekurprivatedata.com and https://sekur.com; Twitter: @sekurprivate.

About New to The Street:

New to The Street is an FMW Media production that operates one of the longest-running US and International sponsored and syndicated Nielsen-rated programming television brands, "New to The Street." Since 2009, New to The Street has run biographical interview segment shows across major U.S. television networks. The Nielsen-rated and sponsored broadcast programming platform reaches millions of homes in the US and international markets. FMW's New to The Street show appears on Bloomberg and the FOX Business Network as sponsored programming. FMW is also one of the nation's largest buyers of linear television, long and short-form paid programming - https://www.newtothestreet.com/.

Forward-Looking Statements Disclaimer US/Canada:

This press release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements do not guarantee future performance or results and will not necessarily be accurate indications of when such performance or results are achieved. This press release should be considered in all filings of the Companies contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as "seek," "anticipate," "believe," "plan," "estimate," "expect," "likely," and "intend" and statements that an event or result "may," "will," "should," "could" or "might" occur or be achieved and other similar expressions. These statements reflect management's current beliefs and are based on information currently available to management as of the date hereof. Forward-looking information in this press release includes, without limiting, the foregoing expectations. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

FMW Media Contact:Monica Brennanmonica@NewtoTheStreet.com1-917-330-2564

"New to The Street" Business Development Office1-516-696-5900Support@NewToTheStreet.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48826ba7-0b59-449f-9f40-cf308f428f8a

Tonix Pharmaceuticals (NASDAQ:TNXP)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 4월(4) 2024 Tonix Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Tonix Pharmaceuticals (NASDAQ:TNXP)
과거 데이터 주식 차트
부터 4월(4) 2023 으로 4월(4) 2024 Tonix Pharmaceuticals 차트를 더 보려면 여기를 클릭.